Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
Clinical breast cancer risk prediction models for women with a high-risk benign breast diagnosis
批准号:
10719777
负责人:
Brian L Sprague
金额:
$84.03万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-19 至 2028-08-31
关键词:
AddressAffectAgeBenignBiopsyBreastBreast Cancer DetectionBreast Cancer Risk FactorBreast Cancer Surveillance ConsortiumBreast DiseasesBreast biopsyCaringCase ManagementCharacteristicsChemopreventionClinicalClinical ManagementCore BiopsyDataDatabasesDecision AnalysisDescriptorDetectionDevelopmentDiagnosisDiagnostic ImagingEnsureExcisionFutureGeographyGoalsGuidelinesHarm ReductionHealth PersonnelHealth care facilityHealthcare SystemsIncidenceInfrastructureInstitutionInterventionLearningLesionLiteratureMalignant - descriptorMalignant NeoplasmsMammographyMedical RecordsModelingMulticenter StudiesNeedlesNon-MalignantNoninfiltrating Intraductal CarcinomaNormal RangeOperative Surgical ProceduresOutcomePalpablePathologicPathology ReportPatientsPolicy MakerPopulationPreventionQualitative MethodsRadiologic FindingRadiology SpecialtyRecommendationRecordsRegional CancerRegistriesReportingReproducibilityRiskSample SizeSamplingSpecific qualifier valueStatistical ModelsSymptomsTimeUncertaintyVacuumValidationWomanWorkbreast cancer diagnosisbreast densitybreast imagingbreast lesionbreast pathologycalcificationcancer diagnosiscancer riskclinical practicecohortcostdisease diagnosisevidence based guidelineshigh riskimprovedinsightinterestlearning strategymalignant breast neoplasmmammography registrymodel developmentmultidisciplinaryneoplasm registrypredictive modelingrisk prediction modelside effectstakeholder perspectivessurveillance imaging
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY/ABSTRACT
Over 1.7 million core needle breast biopsies are performed in the U.S. every year among women with either a
palpable mass or a suspicious finding on breast imaging.1 Benign breast disease is diagnosed in 75% of these
biopsies2 and comprises a spectrum of diagnoses ranging from normal or non-proliferative changes to
proliferative changes with or without atypical features. Early studies demonstrated that ~10-30% of women with
specific benign breast disease diagnoses (referred to as “high-risk lesions”) had cancer identified on surgical
excision of their lesion (referred to as “upgrade”).3,4 Thus, aggressive management with surgical excision is
common for these high-risk lesions to rule out malignancy.1 However, there is widespread interest in avoiding
surgery for high-risk lesions, the majority of which will not yield a malignant diagnosis on excision.5 Single-
institution studies have identified various patient, pathologic, and radiologic variables associated with risk of
upgrade on excision, but insufficient evidence is available to inform evidence-based guidelines as to which
patients with high-risk lesions can safely avoid excision.5-7 There is also uncertainty about long-term breast
cancer risk and the need for enhanced prevention and detection strategies among women who do not undergo
excision, or who undergo excision without upgrade.8-10 Our goal is to provide definitive new evidence to guide
clinical management recommendations for high-risk breast lesions. We propose a comprehensive study
leveraging the rich infrastructure and longitudinal data of the Breast Cancer Surveillance Consortium, a large
U.S. alliance of breast imaging and pathology registries. We will supplement the existing BCSC database with
newly collected data from breast imaging reports, pathology reports, and other clinical medical records for over
7,000 high-risk lesions diagnosed at more than 100 healthcare facilities since 2010. Using an ensemble
learning approach we will develop and validate prediction models for risk of upgrade on excision (Aim 1) and 5-
year breast cancer incidence among women with high-risk lesions (Aim 2) based on patient, pathologic, and
radiologic factors. In Aim 3 we will use a decision analysis framework paired with qualitative study of
stakeholder perspectives to evaluate the potential population impact and acceptability of risk-based strategies
for managing high-risk lesions. Our results will facilitate identification of women with acceptably low risk of
upgrade on excision who can be safely managed by imaging surveillance, and identify women with elevated
risk of a future cancer diagnosis who need enhanced long-term imaging surveillance and/or chemoprevention.
The proposed study will be far larger and more representative of clinical practice in the U.S. than any study
conducted to date, and will be the first to comprehensively evaluate patient, biopsy, pathologic, and radiologic
factors in relation to high-risk lesion outcomes in a multicenter study. Evidence generated by this study will
inform clinical recommendations for the management of high-risk lesions diagnosed with core needle biopsy,
resulting in improved care and reduced harms for the >100,000 women diagnosed annually in the U.S.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
-
批准号:10113566
-
项目类别:
-
资助金额:$67.5万
-
财政年份:2020
-
负责人:Brian L Sprague
-
依托单位:
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
-
批准号:10359684
-
项目类别:
-
资助金额:$64.94万
-
财政年份:2020
-
负责人:Brian L Sprague
-
依托单位:
Identifying effective risk-based supplemental ultrasound screening strategies for women with dense breasts
-
批准号:10555224
-
项目类别:
-
资助金额:$64.18万
-
财政年份:2020
-
负责人:Brian L Sprague
-
依托单位:
Estimating the impact of mammography screening disruptions during the COVID-19 pandemic
-
批准号:10171213
-
项目类别:
-
资助金额:$18.0万
-
财政年份:2020
-
负责人:Brian L Sprague
-
依托单位:
Vermont Breast Cancer Molecular Characterization Laboratory
-
批准号:10253243
-
项目类别:
-
资助金额:$58.76万
-
财政年份:2015
-
负责人:Brian L Sprague
-
依托单位:
Vermont Breast Cancer Molecular Characterization Laboratory
-
批准号:9551743
-
项目类别:
-
资助金额:$31.2万
-
财政年份:2015
-
负责人:Brian L Sprague
-
依托单位:
Vermont Breast Cancer Molecular Characterization Laboratory
-
批准号:9142299
-
项目类别:
-
资助金额:$81.29万
-
财政年份:2015
-
负责人:Brian L Sprague
-
依托单位:
Vermont Breast Cancer Molecular Characterization Laboratory
-
批准号:8928679
-
项目类别:
-
资助金额:$71.72万
-
财政年份:2015
-
负责人:Brian L Sprague
-
依托单位:
Vermont Breast Cancer Molecular Characterization Laboratory
-
批准号:9334814
-
项目类别:
-
资助金额:$74.13万
-
财政年份:2015
-
负责人:Brian L Sprague
-
依托单位:
Vermont Administrative Core
-
批准号:8715713
-
项目类别:
-
资助金额:$15.39万
-
财政年份:2014
-
负责人:Brian L Sprague
-
依托单位:
Breast density and collagen alignment as predictors of DClS disease-free survival
-
批准号:8715710
-
项目类别:
-
资助金额:$11.03万
-
财政年份:2014
-
负责人:Brian L Sprague
-
依托单位:
Vermont Screening Process Documentation Unit
-
批准号:8567652
-
项目类别:
-
资助金额:$43.4万
-
财政年份:2012
-
负责人:Brian L Sprague
-
依托单位:
Vermont Administrative Core
-
批准号:8567658
-
项目类别:
-
资助金额:$13.16万
-
财政年份:2012
-
负责人:Brian L Sprague
-
依托单位:
Vermont PROSPR Research Center (VPRC)
-
批准号:8337733
-
项目类别:
-
资助金额:$94.49万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Breast density and collagen alignment as predictors of DClS disease-free survival
-
批准号:8258529
-
项目类别:
-
资助金额:$13.55万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Vermont PROSPR Research Center (VPRC)
-
批准号:8715708
-
项目类别:
-
资助金额:$116.75万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Vermont PROSPR Research Center (VPRC)
-
批准号:8223448
-
项目类别:
-
资助金额:$129.39万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Breast density and collagen alignment as predictors of DClS disease-free survival
-
批准号:8555418
-
项目类别:
-
资助金额:$12.05万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Vermont PROSPR Research Center (VPRC)
-
批准号:8531194
-
项目类别:
-
资助金额:$115.04万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
Vermont PROSPR Research Center (VPRC)
-
批准号:8847298
-
项目类别:
-
资助金额:$107.22万
-
财政年份:2011
-
负责人:Brian L Sprague
-
依托单位:
海外基金